Viewing Study NCT00468767

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 12:35 AM
Ignite Modification Date: 2026-02-03 @ 6:53 AM
Study NCT ID: NCT00468767
Status: COMPLETED
Last Update Posted: 2008-04-02
First Post: 2007-05-01
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation
Sponsor: Advanz Pharma
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Atrial Fibrillation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Atrial fibrillation View
None RSD1235 View
None Atrial fibrillation of 3 hours to 7 days duration. View
None Atrial fibrillation of 3 hours to 45 days duration. View